Core Insights - The assisted reproductive concept sector saw a rise of 1.11%, ranking 9th among concept sectors, with 47 stocks increasing in value, including notable gains from companies like Kaineng Health (20% limit up), Zhongsheng Pharmaceutical, and Zhongyuan Harmony, which also hit the limit up [1][2] Group 1: Market Performance - The assisted reproductive sector had a net inflow of 1.149 billion yuan, with 36 stocks receiving net inflows, and 6 stocks exceeding 50 million yuan in net inflow [2] - Zhongsheng Pharmaceutical led the net inflow with 436 million yuan, followed by Zhongyuan Harmony, Hengrui Medicine, and Kaineng Health with net inflows of 220 million yuan, 192 million yuan, and 174 million yuan respectively [2][3] Group 2: Stock Performance - The top performers in the assisted reproductive sector included Kaineng Health (20% limit up), Zhongsheng Pharmaceutical (10.02% increase), and Zhongyuan Harmony (10% increase) [1][3] - The stocks with the largest declines included Haichen Pharmaceutical (-4.96%), Sichuan Shuangma (-3.23%), and Rendu Biotechnology (-2.08%) [1][3] Group 3: Capital Flow Ratios - The highest net inflow ratios were observed in Zhongyuan Harmony (25.74%), Kaineng Health (17.57%), and Zhongsheng Pharmaceutical (14.67%) [3][4]
11.49亿主力资金净流入,辅助生殖概念涨1.11%